Targeting AML Mitochondria by Ceramide

通过神经酰胺靶向 AML 线粒体

基本信息

  • 批准号:
    10546239
  • 负责人:
  • 金额:
    $ 40万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-01 至 2024-08-31
  • 项目状态:
    已结题

项目摘要

SUMMARY This proposal's long-term objective is to develop a mechanism-based therapeutic drug for the treatment of human acute myeloid leukemias (AML), which are among the deadliest cancers in the United States. Despite some advances in treatment, survival for AML has not improved significantly in decades, with rare exceptions for specific subclasses. While targeted therapies with FLT3, IDH, and Bcl-2 inhibitors have increased response rates significantly, survival has been extended only by several months. Thus, novel and innovative therapeutic drugs are needed to improve the survival outcomes of AML patients. The sphingolipid ceramide, an emerging tumor suppressor lipid, mediates anti-proliferative signaling events in response to various stress stimuli, including tyrosine kinase inhibitors (TKIs). Our published and unpublished data suggest that decreased levels of C18-ceramide might be critical in the pathophysiology, progression and drug-resistance of AML. These data also revealed that reconstitution of C18-ceramide by molecular and pharmacologic tools results in the suppression of AML growth, and help overcome drug resistance. Because of pharmacologic challenges of the conventional exogenous short-chain ceramides, we have developed novel mitochondrial targeted pyridinium- C18-ceramide (Pyr-Cer) analogs that induce cancer cell mitophagy and tumor suppression. These Pyr-Cer analogs exhibit increased water solubility, cell-membrane permeability, and cancer cell-selective mitochondrial uptake, compared to uncharged conventional ceramides. Pyr-Cer analog drugs, such as LCL461 (patented Class I) or LCL768 (Class II), contain a positive charge at a delocalized pi-electron system. This then results in preferential localization of the drug into highly negatively charged mitochondria in cancer cells/tissues due to the Warburg effect. The accumulation of Pyr-Cer in mitochondria results in cancer cell death via induction of mitophagy by reducing cellular energy generation and decreasing the synthesis of other vital macromolecules, such as nucleotides. This effect of Pyr-Cer on mitophagy induction is further increased when cancer cells are exposed to general ROS/RNS inducer sodium selenite that causes Drp1 activation and mitochondrial fission. Thus, we have generated a new (Class II) Pyr-Cer analog drugs conjugated with sodium selenite, named as SoSe-C18-Pyr-Cer (LCL768), which selectively induced mitophagy-dependent cell death in AML in situ and in vivo. Based on these data, our goal is to develop LCL768 as an anti-cancer drug for the treatment of AML. In these feasibility studies, we will: 1) Validate the mechanism by which Pyr-Cer drugs target AML mitochondria by mitophagy in vitro; and 2) Determine bioactivity, toxicity, pharmacokinetics and anti-AML activity of LCL768 in vivo. We will determine the possible off-target effects, maximum tolerated dose (MTD), pharmacokinetic/pharmacodynamic profiles and anti-AML effects of LCL768 in various models. These include drug sensitive versus resistant AML xenografts, AML PDXs, and primary AML blasts. This Phase I feasibility study will help the commercial development of LCL768 for a Phase II application.
总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Besim Ogretmen其他文献

Besim Ogretmen的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Besim Ogretmen', 18)}}的其他基金

Sphingolipid Metabolism and Signaling in the Regulation of Senescence and Aging
鞘脂代谢和信号传导在衰老和衰老调节中的作用
  • 批准号:
    10253130
  • 财政年份:
    2020
  • 资助金额:
    $ 40万
  • 项目类别:
Ceramide Signaling in the Regulation of Head & Neck Cancer Cell Death and Therapy
头部调节中的神经酰胺信号传导
  • 批准号:
    9930853
  • 财政年份:
    2019
  • 资助金额:
    $ 40万
  • 项目类别:
Ceramide metabolism and the regulation of TGF-beta receptor signaling to control metastasis
神经酰胺代谢和调节 TGF-β 受体信号传导以控制转移
  • 批准号:
    10411382
  • 财政年份:
    2018
  • 资助金额:
    $ 40万
  • 项目类别:
Ceramide metabolism and the regulation of PD-L1 signaling to control metastasis and resistance to immunotherapy in TNBC
神经酰胺代谢和 PD-L1 信号调节以控制 TNBC 的转移和免疫治疗耐药
  • 批准号:
    10801345
  • 财政年份:
    2018
  • 资助金额:
    $ 40万
  • 项目类别:
Ceramide metabolism and the regulation of TGF-beta receptor signaling to control metastasis
神经酰胺代谢和调节 TGF-β 受体信号传导以控制转移
  • 批准号:
    9977980
  • 财政年份:
    2018
  • 资助金额:
    $ 40万
  • 项目类别:
Ceramide metabolism and the regulation of TGF-beta receptor signaling to control metastasis
神经酰胺代谢和调节 TGF-β 受体信号传导以控制转移
  • 批准号:
    10222592
  • 财政年份:
    2018
  • 资助金额:
    $ 40万
  • 项目类别:
Ceramide metabolism and the regulation of TGF-beta receptor signaling to control metastasis
神经酰胺代谢和调节 TGF-β 受体信号传导以控制转移
  • 批准号:
    10460230
  • 财政年份:
    2018
  • 资助金额:
    $ 40万
  • 项目类别:
Ceramide metabolism and the regulation of TGF-beta receptor signaling to control metastasis
神经酰胺代谢和调节 TGF-β 受体信号传导以控制转移
  • 批准号:
    9441547
  • 财政年份:
    2018
  • 资助金额:
    $ 40万
  • 项目类别:
Development of Novel Cancer Therapeutics by Targeting Sphingolipid Signaling
通过靶向鞘脂信号传导开发新型癌症疗法
  • 批准号:
    9072008
  • 财政年份:
    2016
  • 资助金额:
    $ 40万
  • 项目类别:
Project 2: Regulation of Tumor Metastasis by Systemic S1P and Complement Signaling
项目2:系统性S1P和补体信号调节肿瘤转移
  • 批准号:
    9072014
  • 财政年份:
    2016
  • 资助金额:
    $ 40万
  • 项目类别:

相似海外基金

RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 40万
  • 项目类别:
    Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 40万
  • 项目类别:
    Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
  • 批准号:
    BB/Z514391/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40万
  • 项目类别:
    Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
  • 批准号:
    ES/Z502595/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40万
  • 项目类别:
    Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
  • 批准号:
    ES/Z000149/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40万
  • 项目类别:
    Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
  • 批准号:
    23K24936
  • 财政年份:
    2024
  • 资助金额:
    $ 40万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
  • 批准号:
    2901648
  • 财政年份:
    2024
  • 资助金额:
    $ 40万
  • 项目类别:
    Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
  • 批准号:
    2301846
  • 财政年份:
    2023
  • 资助金额:
    $ 40万
  • 项目类别:
    Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 40万
  • 项目类别:
    Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
  • 批准号:
    23K16076
  • 财政年份:
    2023
  • 资助金额:
    $ 40万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了